Regeneron Pharmaceuticals (NASDAQ:REGN) Sets New 12-Month Low – Here’s What Happened

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)’s share price reached a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $640.28 and last traded at $638.59, with a volume of 349031 shares. The stock had previously closed at $661.00.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on REGN shares. Bank of America reiterated an “underperform” rating and issued a $565.00 target price on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 10th. UBS Group lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $1,130.00 to $738.00 in a report on Thursday, January 16th. Truist Financial lowered their target price on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a report on Wednesday, January 8th. Piper Sandler cut their price target on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating on the stock in a research note on Monday, January 27th. Finally, Canaccord Genuity Group cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 17th. One research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $973.13.

Regeneron Pharmaceuticals Price Performance

The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The business’s 50-day moving average price is $688.31 and its two-hundred day moving average price is $809.71. The firm has a market cap of $69.33 billion, a price-to-earnings ratio of 16.57, a P/E/G ratio of 2.34 and a beta of 0.27.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping the consensus estimate of $11.21 by $0.86. The company had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period last year, the business earned $11.86 EPS. On average, research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.56%. The ex-dividend date was Thursday, February 20th. Regeneron Pharmaceuticals’s payout ratio is currently 2.30%.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Raymond James Trust N.A. increased its stake in Regeneron Pharmaceuticals by 2.9% during the third quarter. Raymond James Trust N.A. now owns 1,064 shares of the biopharmaceutical company’s stock valued at $1,119,000 after purchasing an additional 30 shares during the last quarter. Great Valley Advisor Group Inc. raised its stake in Regeneron Pharmaceuticals by 5.0% during the third quarter. Great Valley Advisor Group Inc. now owns 442 shares of the biopharmaceutical company’s stock worth $465,000 after acquiring an additional 21 shares during the period. Cerity Partners LLC raised its stake in Regeneron Pharmaceuticals by 18.5% during the third quarter. Cerity Partners LLC now owns 15,548 shares of the biopharmaceutical company’s stock worth $16,344,000 after acquiring an additional 2,423 shares during the period. Kingsview Wealth Management LLC boosted its stake in Regeneron Pharmaceuticals by 2.6% in the third quarter. Kingsview Wealth Management LLC now owns 860 shares of the biopharmaceutical company’s stock valued at $904,000 after acquiring an additional 22 shares during the period. Finally, Pitcairn Co. grew its holdings in shares of Regeneron Pharmaceuticals by 4.8% during the third quarter. Pitcairn Co. now owns 962 shares of the biopharmaceutical company’s stock valued at $1,011,000 after purchasing an additional 44 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.